Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) is projected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Tyra Biosciences to post earnings of ($0.54) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 3:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Price Performance

Shares of TYRA stock opened at $36.52 on Tuesday. The firm’s 50-day simple moving average is $32.26 and its 200-day simple moving average is $23.15. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $39.15. The firm has a market cap of $1.97 billion, a P/E ratio of -18.17 and a beta of 1.06.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Commodore Capital LP boosted its position in Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after purchasing an additional 2,150,000 shares during the period. Farallon Capital Management LLC raised its position in Tyra Biosciences by 80.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after purchasing an additional 923,000 shares during the period. Caligan Partners LP lifted its stake in shares of Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after purchasing an additional 506,875 shares in the last quarter. Balyasny Asset Management L.P. lifted its stake in shares of Tyra Biosciences by 139.8% during the second quarter. Balyasny Asset Management L.P. now owns 583,386 shares of the company’s stock worth $5,583,000 after purchasing an additional 340,142 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Tyra Biosciences by 74.9% in the fourth quarter. State Street Corp now owns 749,463 shares of the company’s stock worth $19,703,000 after buying an additional 320,991 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TYRA shares. Wedbush upped their price target on shares of Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Cantor Fitzgerald started coverage on shares of Tyra Biosciences in a research note on Tuesday, February 24th. They set an “overweight” rating for the company. Barclays started coverage on Tyra Biosciences in a report on Tuesday, January 27th. They set an “overweight” rating for the company. Jefferies Financial Group increased their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Finally, William Blair began coverage on Tyra Biosciences in a research report on Tuesday, February 10th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.67.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.